



Report #:

IF-824-QSA-TR008-2026-094-03

Page 1 of 1

Title:

## Certificate of Analysis (CoA)

### Bacterial Endotoxins Test (ABI- TEST 0012)

**Date:** 2/21/2026  
**Date Tested:** 2/19/2026  
**Customer:** Finnrick  
**Testing material:** Tesamorelin  
**Lot Number:** YV5MGBT  
**BT Sample ID:** 005000038919434  
**Labeled Peptide:**  
**Content/Potency:** 20 mg  
**Storage:** R.T.  
**Packing material:** small clear vial: white sample, white label, bright red crimp, red plastic cap.  
**Labeled as:** Tesamorelin  
**Manufacturer:** N/A  
**Testing Purpose:** (ABI-TEST 0012) test quantifies bacterial endotoxin levels to confirm that the product does not elicit pyrogenic reactions, maintaining patient safety and product integrity.



| Test                             | Method   | Specification            | Result |
|----------------------------------|----------|--------------------------|--------|
| <b>Bacterial Endotoxins Test</b> | USP <85> | 40 EU/vial reconstituted | PASS   |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

### Bacterial Endotoxins Test Tesamorelin Lot YV5MGBT

| Sample ID       | Description | Volume (mL) | Endotoxin Limit (EU/vial) | Lysate Sensitivity ( $\lambda$ , EU/mL) | Result       |
|-----------------|-------------|-------------|---------------------------|---|--------------|
| 005000038919434 | Tesamorelin | 3           | 40 EU/vial                | 0.25                                    | 15.8 EU/vial |

The sample passed a valid gel clot endotoxin test based on the type, mode of administration and dosage.

**Andrea Castro, AS**

Digitally signed by Andrea Castro, AS  
 DN: OU=BTLabs, O=Finntest Inc., CN=Andrea Castro, AS, E=acastro@btlabs.us  
 Reason: I am approving this document  
 Location:  
 Date: 2026.02.23 00:21:41  
 0000  
 Fossil PDF Reader Version: 2025.1.0

Andrea Castro, AS  
 Scientist-I  
 BTLabs

**Verna Zheng, AS**

Digitally signed by Verna Zheng, AS  
 DN: CN=Verna Zheng, AS, E=vzheng@btlabs.us  
 Reason: I am the author of this document  
 Location:  
 Date: 2026.02.23 20:30:50  
 0000  
 Fossil PDF Reader Version: 2025.1.0

Verna Zheng, AS  
 Scientist-I  
 BTLabs

5730 Corporate Way | Suite 220 | West Palm Beach, FL 33407  
 Phone: (561) 625-0133  
 E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>

IF-824-QSA-TB004

Rev 1.0 January 2025



Report #:

IF-824-QSA-TR006-2026-94-80

Page 1 of 2

Title:

## Certificate of Analysis (CoA)

**Date:** 3/02/2026  
**Date Tested:** 3/02/2026  
**Customer:** Finnrick  
**Testing material:** Tesamorelin  
**Lot Number:** YV5MGBT  
**BT Sample ID:** 005000038919434

**Labeled Peptide Content/Potency:** 20 mg  
**Storage:** R.T.  
**Packing material:** small clear vial; white sample, white label, bright red crimp, red plastic cap.

**Labeled as:** Tesamorelin  
**Manufacturer:** N/A

**Testing Purpose:** FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



| Test   | Method     | Specification  | Result   |
|--|------------|--|--|
| General Appearance                           | USP <630>  | white powder   | white powder   |
| Mass   | USP <41>   | As recorded  | 65.6 mg  |
| FTIR Identification and Composition Analysis | USP <197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of Tesamorelin with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay                 | USP <621>  | Specifications: $\geq 98\%$  | 99.8 %   |
| HPLC Potency Assay                           | USP <621>  | Specifications: 95 – 105% of 20 mg   | 19.4 mg (97.3 %)   |
| Peptide-to-Excipients Ratio                  | USP <1151> | Specifications: Ratios of 1:2 to 1:10 peptide: excipients                      | 19.4 : 46.2 mg (1:2.4)   |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

**Andrea Castro, AS**

Digitally signed by Andrea Castro, AS  
 DN: OU=BT Labs, O=BT Labs, Inc., CN=Andrea Castro, AS, E=acastro@bttools.us  
 Reason: I am approving this document  
 Location: Date: 2026.03.02 12:55:24 -0500  
 Post PDF Reader Version: 2025.1.2

Andrea Castro, AS  
 Scientist-I  
 BTLabs

**Verna Zheng, AS**

Digitally signed by Verna Zheng, AS  
 DN: CN=Verna Zheng, AS, E=vzheng@bttools.us  
 Reason: I am the author of this document  
 Location: Date: 2026.03.02 12:56:05 -0500  
 Post PDF Reader Version: 2025.1.2

Verna Zheng, AS  
 Scientist-I  
 BTLabs

5730 Corporate Way | Suite 220 | West Palm Beach, FL 33407  
 Phone: (561) 625-0133  
 E-mail: [info@btlabeltesting.com](mailto:info@btlabeltesting.com) | Website: <https://btlabeltesting.com>

IF-824-QSA-TR006  
 Rev 1.0 January 2025



Report #:


IF-824-QSA-TR006-2026-94-80

Page 2 of 2


Title:

### Certificate of Analysis (CoA)

#### FTIR ID and Composition Analysis: Tesamorelin Lot YV5MGBT



#### HPLC Purity and Potency Assay @ 280 nm: Tesamorelin Lot YV5MGBT



#### Tesamorelin Lot YV5MGBT @ 280 nm

| Peak #: | Retention Time (min) | Area (mAU*s) |
|---------|----------------------|--------------|
| 1       | 6.067                | 532.1        |

5730 Corporate Way | Suite 220 | West Palm Beach, FL 33407

Phone: (561) 625-0133

E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>

IF-824-QSA-TR006  
Rev 1.0 January 2025